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A B S T R A C T
Background
A peripheral venous catheter (PVC) is typically used for short-term delivery of intravascular fluids and medications. It is an essential
element of modern medicine and the most frequent invasive procedure performed in hospitals. However, PVCs often fail before
intravenous treatment is completed: this can occur because the device is not adequately attached to the skin, allowing the PVC to fall
out, leading to complications such as phlebitis (irritation or inflammation to the vein wall), infiltration (fluid leaking into surrounding
tissues) or occlusion (blockage). An inadequately secured PVC also increases the risk of catheter-related bloodstream infection (CRBSI),
as the pistoning action (moving back and forth in the vein) of the catheter can allow migration of organisms along the catheter and
into the bloodstream. Despite the many dressings and securement devices available, the impact of different securement techniques for
increasing PVC dwell time is still unclear; there is a need to provide guidance for clinicians by reviewing current studies systematically.
Objectives
To assess the effects of PVC dressings and securement devices on the incidence of PVC failure.
Search methods
We searched the following electronic databases to identify reports of relevant randomised controlled trials (RCTs): the Cochrane
Wounds Group Register (searched 08 April 2015): The Cochrane Central Register of Controlled Trials (CENTRAL; 2015, Issue 3),
Ovid MEDLINE (1946 to March 7 2015); Ovid MEDLINE (In-Process & Other Non-Indexed Citations, March 7 2015); Ovid
EMBASE (1974 to March 7 2015); and EBSCO CINAHL (1982 to March 8 2015).
Selection criteria
RCTs or cluster RCTs comparing different dressings or securement devices for the stabilisation of PVCs. Cross-over trials were ineligible
for inclusion, unless data for the first treatment period could be obtained.
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Data collection and analysis
Two review authors independently selected studies, assessed trial quality and extracted data. We contacted study authors for missing
information. We used standard methodological procedures expected by Cochrane.
Main results
We included six RCTs (1539 participants) in this review. Trial sizes ranged from 50 to 703 participants. These six trials made four
comparisons, namely: transparent dressings versus gauze; bordered transparent dressings versus a securement device; bordered transparent
dressings versus tape; and transparent dressing versus sticking plaster. There is very low quality evidence of fewer catheter dislodgements
or accidental removals with transparent dressings compared with gauze (two studies, 278 participants, RR 0.40; 95% CI 0.17 to 0.92,
P = 0.03%). The relative effects of transparent dressings and gauze on phlebitis (RR 0.89; 95% CI 0.47 to 1.68) and infiltration (RR
0.80; 95% CI 0.48 to 1.33) are unclear. The relative effects on PVC failure of a bordered transparent dressing and a securement device
have been assessed in only one small study and these were unclear. There was very low quality evidence from the same single study of less
frequent dislodgement or accidental catheter removal with bordered transparent dressings than securement devices (RR 0.14, 95% CI
0.03 to 0.63) but more phlebitis with bordered dressings (RR 8.11, 95% CI 1.03 to 64.02) (very low quality evidence). A small single
study compared bordered transparent dressings with tape and found very low quality evidence of more PVC failure with the bordered
dressing (RR 1.84, 95% CI 1.08 to 3.11) but the relative effects on dislodgement were not clear (very low quality evidence). The relative
effects of transparent dressings and a sticking plaster have only been compared in one small study and are unclear. More high quality
RCTs are required to determine the relative effects of alternative PVC dressings and securement devices.
Authors’ conclusions
It is not clear if any one dressing or securement device is better than any other in securing peripheral venous catheters. There is a need
for further, independent high quality trials to evaluate the many traditional as well as the newer, high use products. Given the large cost
differences between some different dressings and securement devices, future trials should include a robust cost-effectiveness analysis.
P L A I N L A N G U A G E S U M M A R Y
Effectiveness of dressings and other devices that are used to keep a peripheral venous catheter in place
Background
Most people admitted to an acute/emergency hospital ward require the insertion of a peripheral venous catheter/cannula (PVC), often
known as a ’drip’ or ’IV’. A PVC is a flexible, hollow, plastic tube that is inserted in a peripheral vein, most commonly in the hand, or
lower arm. Up to half of all PVCs stop working before treatment has finished and a new one has to be inserted. This is uncomfortable
for the patient and costly for the healthcare system. One of the reasons PVCs fail, is that the products used to hold them in place are
not fully effective, and allow the PVC to move around. This movement causes redness, inflammation and even blood infections. The
PVC can become blocked, or leak into the surrounding tissues, or even fall out as a consequence of the movement. The function of
PVC dressings and/or securement devices is to keep the PVC in the vein, and to cover the insertion site so that it is kept dry and clean
and protected from infection.
Review question
We reviewed the evidence about the effect that different PVC dressings and securement devices have on PVC failure rates.
Study characteristics
We searched the medical literature for studies that compared different types of products that are used to keep PVCs in place. We found
six studies (involving 1539 participants) that compared four different ways of securing PVCs. These included:
1. a plain transparent film dressing compared with a gauze (woven fabric) dressing;
2. a bordered transparent dressing (clear transparent window with a reinforced fabric edge) compared with a securement device (that
has anchor points or clips that hold the PVC in place over a strong adhesive base pad on the skin) that is used in conjunction with a
transparent film dressing;
3. a bordered transparent dressing compared with non-sterile medical tape;
4. a plain transparent film dressing compared with sticking plaster.
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The participants in the studies were both adults and children on medical and surgical wards. There were no studies based in emergency
departments.
Key results
Two studies provided very low quality evidence that PVCs were less likely to fail when a transparent dressing was used rather than
gauze.
Other positive outcomes favouring one dressing over another were based on the results of very low quality, single studies. Overall there is
a lack of high quality evidence and continued uncertainty regarding the best methods of securing a peripheral venous catheter remains.
More high quality research is needed in this area.
Quality of the evidence
We assessed a number of quality indicators regarding the methods used in each study and graded the overall quality of studies as very
low. Each study had a high or unclear risk of bias for some of the quality indicators. For example, it is likely that clinical staff responsible
for assessing participants’ outcomes knew the treatment group to which each person belonged, as the securement methods for PVCs
looked different.
There were only a limited number of studies available for consideration in this review, and they did not investigate some securement
products that are in common use.
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S U M M A R Y O F F I N D I N G S F O R T H E M A I N C O M P A R I S O N [Explanation]
Transparent dressing versus gauze for securing peripheral venous catheters
Patient or population: Patients requiring a peripheral venous catheter
Settings: Hospital or community
Intervention: Transparent dressing
Comparison: Gauze dressing
Outcomes Illustrative comparative risks* (95% CI) Relative effect
(95% CI)
No of Participants
(studies)
Quality of the evidence
(GRADE)
Comments
Assumed risk Corresponding risk
Gauze Transparent dressing
PVC failure This outcome was not reported Not estimable - See comment ’PIVC failure’is a compos-
ite measure
Dislodgement/
accidental removal
Study population RR 0.4
(0.17 to 0.92)
278
(2 studies)
⊕©©©
very low1,2,3
134 per 1000 54 per 1000
(23 to 123)
Phlebitis Study population RR 0.89
(0.47 to 1.68)
379
(3 studies)
⊕©©©
very low1,2,4,5
87 per 1000 78 per 1000
(41 to 146)
*The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% confidence interval) is based on the
assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).
CI: Confidence interval; RR: Risk ratio;
GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our confidence in the estimate of effect.
Moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.
Low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.
Very low quality: We are very uncertain about the estimate.
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1 Downgraded due to risk of bias (one level): Unblinded personnel and outcome assessors
2 Downgraded due to risk of bias (one level): Unclear if allocation to groups was blinded
3 Downgraded due to imprecision (one level): The 95% confidence intervals ranged from 0.17 to 0.92
4 Downgraded due to risk of bias (one level): Catheters may have been in situ when participants were enrolled consequently, the outcome
may have been due to the previous dressing
5 Downgraded due to imprecision (one level): The 95% confidence intervals ranged from 0.47 to 1.68; indicating that the true estimate
of effect lies somewhere between a reduction of 53% or an increase of 68% in the incidence of phlebitis when a transparent dressing is
used.
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B A C K G R O U N D
Description of the condition
A peripheral venous catheter (PVC), often referred to as an intra-
venous cannula, drip or IV, is a flexible, hollow, plastic tube that is
inserted in a peripheral vein, most commonly the metacarpal vein
of the hand, and alternatively, either the cephalic or basilic vein
of the lower forearm (Tagalakis 2002; Dougherty 2008; O’Grady
2011). PVCs are typically used for short-term delivery of intravas-
cular fluids and medications. PVCs are an essential element of
modern medicine and their insertion is the most frequent inva-
sive procedure performed in hospitals, with over 60% of all hos-
pitalised patients requiring one (Wilson 2006). It has been con-
servatively estimated that patients have a PVC for 15% to 20% of
the total time they spend in an acute care hospital (Zingg 2009).
In the USA, an estimated 330 million PVCs are sold each year
(Hadaway 2012).
The Infusion Nurses Society Standards of Practice recommend
that PVCs be re-sited when clinically indicated, and that deci-
sions about when to re-site should be based on an assessment of
the patient’s PVC site, including: skin and vein integrity, type of
intravenous (IV) therapy prescribed, the treatment setting, and
patency of the PVC and securing dressing or stabilisation device
(INS 2011). PVCs often fail before intravenous treatment is com-
pleted. Reported failure rates, or unscheduled restarts, range from
33% to 69% (Harwood 1992; Royer 2003; Smith 2006; Bolton
2010; Rickard 2010). PVCs fail for a wide range of reasons; the
most commonly identified causes of failure are partial dislodge-
ment or accidental removal, phlebitis (irritation or inflammation
to the vein wall), occlusion (blockage), infiltration (fluid moving
into surrounding tissue), leakage and, rarely, infection (Webster
2008; Bolton 2010; Rickard 2010).
Dislodgement and accidental removal
Inadequate catheter stabilisation or securement can lead to poor
attachment of the PVC to the skin, allowing movement of the
catheter in and out of, or around and within, the vein resulting in
partial or complete dislodgement. PVC dislodgement rates have
been reported to range from 6% of PVC insertions to as high as
20% (Wood 1997; Royer 2003; Dillon 2008; Rickard 2010).
Phlebitis
Intravenous therapy can be disrupted by phlebitis, which is the
irritation and inflammation of a vein wall caused by the pres-
ence of the PVC (Monreal 1999; Tagalakis 2002). Phlebitis can
be categorised as chemical (caused by infusates or medication),
bacterial (caused by contamination of the site, catheter, tubing or
IV solution), or mechanical (caused by the action of the catheter
in the vessel; Macklin 2003). An improperly secured PVC that
allows micro-movement of the catheter within the vein can ir-
ritate the vein wall and lead to mechanical phlebitis (Sheppard
1999; Gallant 2006). Phlebitis is characterised by the presence of
any combination of tenderness, pain, erythema (redness), oedema
(swelling), warmth, palpable cord (hard, thickened vein), or pu-
rulent drainage (pus; Maki 1991; Tagalakis 2002; Gallant 2006).
Phlebitis rates range from 2.6% to 67% depending on the au-
thors’ definition, study design, study population and the duration
of follow-up period (Catney 2001; White 2001; Karadeniz 2003;
Malach 2006; Webster 2008; Rickard 2010; Rickard 2012).
Occlusion/infiltration and leakage
A poorly-stabilised PVC within a vein can kink or damage the
vessel wall, instigating the release of thromboplastic substances and
platelets that promote blood clotting (Gabriel 2010). This process
may cause narrowing or occlusion of the catheterised vein, which
then forces the backflow and potential leakage of IV fluids from
the PVC insertion site, or their infiltration into the surrounding
tissues, and restricts future venous access in the limb (Royer 2003;
Gabriel 2010). Recent studies show PVC failure due to occlusion/
infiltration occur in 12%to36%of patients (Homer 1998;Catney
2001; Tagalakis 2002; Webster 2008; Rickard 2010).
Infection
Poor catheter stabilisation, particularly if it leads to unscheduled
PVC re-siting, may increase a patient’s risk of infection. In order to
be sited, a PVCmust be inserted through the patient’s skin, which
normally acts as a protective barrier against bacteria that might
otherwise access the body. Consequently the catheter may be con-
taminated during initial insertion or subsequent re-sitings with a
new PVC (Gabriel 2008). The most common cause of catheter-
related bloodstream infection (CRBSI) in short-term catheters oc-
curs from bacterial entry at the skin site. Micro-organisms can
cause local infection and may track along the surface of the PVC
to contaminate the catheter tip, and then the bloodstream (Morris
2008; O’Grady 2011). Micro-motion while the PVC is in place
may also encourage microbial entry via the PVC wound (Frey
2006). However, CRBSIs occur less frequently in PVC than in
other intravascular devices such as peripherally inserted central
catheters (PICC; 0.1%, 0.5 per 1000 PVC catheter-days com-
pared with 2.4%, 2.1 per 1000 PICC catheter-days; Maki 2006).
The failure of a PVC can lead to venous access difficulties, includ-
ing the need for more frequent PVC re-sites or for a central venous
catheter, and causing interruption to the delivery of IV therapy
and medicines with a potential increase in the duration of hospital
stay and healthcare costs (Monreal 1999; Tagalakis 2002; Dillon
2008).
Description of the intervention
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The intervention of interest is the wound dressing(s) and secure-
ment device(s) used for PVC stabilisation. Following clinical prac-
tice protocols or clinician preference, two standard dressings are
generally used to secure the PVC: either sterile gauze with non
sterile tape or bandage, or a transparent dressing (Gabriel 2010;
O’Grady 2011). Plain non-sterile tape is often used for additional
securement. However, new products, such as antimicrobial-im-
pregnated dressings and sutureless (stitch-less) securement devices
that are designed to be used with the wound dressing to improve
attachment of the PVC to the skin, have recently become avail-
able.
Gauze/tape
A combination of sterile gauze with tape or bandage has been
widely used to secure PVCs. This combination can range from
non-sterile tape and sterile gauze assembled by clinicians us-
ing products such as Micropore® (3M) or Hypafix® (Smith &
NephewHealthcare Ltd), to commercially-available dressings that
combine a sterile tape and gauze design, for example Primapore®
(Smith & Nephew Healthcare Ltd). However, gauze needs to be
removed so that the insertion site can be seen and this can poten-
tially increase the chance of catheter dislodgement or movement,
resulting in complications such as phlebitis, infiltration or occlu-
sion (Campbell 1999). Furthermore, although gauze dressings are
absorbant and can prevent the pooling of moisture at the insertion
site, when wet they provide an ideal environment for the prolifer-
ation of infection-producing organisms (Campbell 1999; Gabriel
2010).
Transparent dressings
Transparent dressings have been in use since the early 1980s and
offer clear visualisation of the PVC insertion site. The Opsite®
(Smith & Nephew Healthcare Ltd) and Tegaderm® (3M) ranges
of dressings are themost commonly used products (Webster 2011).
An early systematic review that compared gauze dressings with
transparent dressings for PVC securement found a significantly
higher infection risk with transparent dressings (Hoffmann 1992).
This was thought to be related to increased collection of moisture
(Hoffmann 1992). As a result of these studies, modern transparent
dressings were developed and it is claimed that they have greater
moisture vapour permeability (MVP; Wille 1993). A study com-
paring standard Opsite and Opsite IV3000 for dressing central
venous catheters reported MVPs of 800 g/m2 and 3000 g/m2, re-
spectively and no differences between the dressings for complica-
tions such as moisture accumulation, lifting of dressing or dura-
bility (Wille 1993). Recently, new versions of these products, with
additional strongly-adhesive fabric borders, or additional sterile
tapes to improve securement, have become available.
Antimicrobial dressings
Antimicrobial dressings or impregnated discs have been developed
to aid prevention of CRBSI, for example Biopatch® (Johnson and
Johnson) and Tegaderm CHG® (3M). The most common source
of infection for CRBSI is colonisation of the skin surrounding the
insertion site, so antimicrobial dressings aim to reduce this coloni-
sation, and thus decrease the incidence of CRBSI (Dainiels 2012).
The Centers for Disease Control and Prevention recommend the
use of a chlorhexidine-impregnated sponge for temporary short-
term catheters (typically used in intensive care units) if the central
line-associated bloodstream infection rates are unacceptably high
and not decreasing despite the implementation of basic preventa-
tive measures (i.e. education and training, maximal sterile barrier
precautions and > 0.5% chlorhexidine in an alcoholic solution for
skin antisepsis; O’Grady 2011). However, there is no mention in
the guidelines of antimicrobial sponge/dressing use in conjunction
with peripheral catheters.
Sutureless securement devices
Sutureless securement devices have incorporated anchor points,
or clips, to hold the PVC in place more securely, for example
Statlock® (Bard Medical), Grip-Lok® (Zefon International) or
Hubguard ® (Centurion Medical Products). It is reported that
these increase attachment to the skin, thus minimising catheter
movement and reducing complications such as phlebitis, dislodge-
ment, infiltration and vessel occlusion (Schears 2006). The Cen-
ters for Disease Control and Prevention have recommended the
use of sutureless securement devices to decrease the risk of infec-
tion (O’Grady 2011). The Infusion Nurses Society advises that a
stabilisation device should be used in preference to tape or sutures
when possible, to aid in maintaining device integrity and minimi-
sation of movement at the catheter hub (INS 2011).
How the intervention might work
The aimof all PVCdressings and securement devices is tomaintain
a barrier to infection and to ensure that the device remains in the
vein. This review aims to examine the different PVC protection
and stabilisation methods; the impact they have on PVC dwell
time and stabilisation-related complications such as dislodgement,
phlebitis, occlusion/infiltration, leaking, and infection; and the
costs involved with the different products. Identification of the
most effective securement method may help reduce stabilisation-
related complications.
Why it is important to do this review
PVC insertion and IV therapy is a common procedure for hospi-
talised patients. Prevention of failure and unscheduled restarts of
PVC therapy is an important patient outcome: failure interrupts
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prescribed therapy, and reinsertion can be distressing and painful.
A PVC that is not securely attached to the skin has the potential to
migrate externally and simply fall out, or cause complications such
as phlebitis and infiltration. An inadequately secured PVC also
increases the risk of CRBSI, as the pistoning action of the catheter
can allow migration of organisms along the catheter and into the
systemic circulation (Gabriel 2001; O’Grady 2011). These un-
necessary complications can lead to delays in treatment and in-
creases in length of hospital stay (Bolton 2010). There is also an
impact on health resources, as PVC replacement is time consum-
ing, requires skilled clinicians and disposable sterile equipment,
and CRBSIs cause significant increases in treatment costs (Bolton
2010; Gabriel 2010). Despite the many dressings and securement
devices available, the impact of different securement techniques
for increasing PVC dwell time is still unclear; there is a need to
provide guidance for clinicians by reviewing current studies sys-
tematically.
O B J E C T I V E S
To assess the effects of PVC dressings and securement devices on
the incidence of PVC failure.
M E T H O D S
Criteria for considering studies for this review
Types of studies
We included randomised controlled trials (RCTs) or cluster ran-
domised trials (where the cluster represented randomisation at the
ward or hospital level), comparing different dressings or secure-
ment devices for the stabilisation of PVCs. Cross-over trials were
ineligible for inclusion, unless data for the first treatment period
could be obtained.
Types of participants
Any patients in any setting who require a PVC.
Types of interventions
Any trial comparing dressings or securement devices with another
dressing or securement device , for the protection or stabilisation
of a PVC. Dressings or securement devices that are made from any
type of product (e.g. polyurethane, gauze) were eligible.
Types of outcome measures
Primary outcomes
• PVC failure (a composite measure of unplanned PVC
removal for any reason, such as phlebitis, infiltration accidental
removal, blockage).
• Adverse events (such as allergic skin reaction; blisters) .
Secondary outcomes
• Dislodgement and accidental removal.
• Time to catheter failure (analysed by survival methods e.g.
Kaplan-Meier survival curves).
• Phlebitis, as identified by the trial investigator.
• Infiltration (the permeation of intravenous fluid or
medication into the surrounding tissue, resulting in swelling).
• Occlusion or inability to administer intravenous fluids.
• Catheter-related blood stream infection (CRBSI) with
laboratory confirmation of the catheter as the source of the
infection (O’Grady 2011).
• Suspected CRBSI, as identified by the trial investigator.
• Entry site local infection, as described by the trial
investigator.
• Skin damage, as described by the trial investigator.
• Cost (including cost or cost-effectiveness estimations, as
well as measurements of resource use such as number of dressing/
device changes, staff time).
• Patient satisfaction (using any validated instrument, e.g. a
visual analogue scale).
• Pain associated with dressing removal.
Search methods for identification of studies
Electronic searches
In April 2015 we searched the following electronic databases to
identify reports of relevant RCTs:
• The Cochrane Wounds Group Specialised Register
(searched 8 April 2015);
• The Cochrane Central Register of Controlled Trials
(CENTRAL; 2015, Issue 3);
• Ovid MEDLINE (1946 to March 7, 2015);
• Ovid MEDLINE (In-Process & Other Non-Indexed
Citations, March 7, 2015)
• Ovid EMBASE (1974 to March 7, 2015);
• EBSCO CINAHL (1982 to March 8, 2015).
We used the following search strategy for CENTRAL (The
Cochrane Library):
#1 MeSH descriptor: [Catheterization, Peripheral] explode all
trees
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#2 (peripheral venous catheter* or PVC):ti,ab,kw
#3 {or #1-#2}
#4 MeSH descriptor: [Occlusive Dressings] explode all trees
#5 (securement device* or Statlock or Hubguard):ti,ab,kw
#6 ((occlusive or gauze or tape or polyurethane or permeable or
nonpermeable or non-permeable or transparent or antimicrobial)
near/3 dressing*):ti,ab,kw
#7 (opsite or tegaderm or micropore or hypafix):ti,ab,kw
#8 {or #4-#7}
#9 {and #3, #8}
The search strategies for Ovid MEDLINE, Ovid EMBASE and
EBSCO CINAHL can be found in Appendix 1.
We adapted this strategy to search Ovid MEDLINE, Ovid EM-
BASE and EBSCO CINAHL. We combined the Ovid MED-
LINE search with the Cochrane Highly Sensitive Search Strategy
for identifying randomised trials in MEDLINE: sensitivity- and
precision-maximising version (2008 revision; Lefebvre 2011). We
combined the EMBASE search with the Ovid EMBASE filter de-
veloped by the UK Cochrane Centre (Lefebvre 2011). We com-
bined the CINAHL searches with the trial filters developed by the
Scottish IntercollegiateGuidelinesNetwork (SIGN2011).We did
not restrict studies with respect to language, date of publication
or study setting.
We searched the following clinical trials registries:
• ClinicalTrials.gov (http://www.clinicaltrials.gov/)
• WHO International Clinical Trials Registry Platform (
http://apps.who.int/trialsearch/Default.aspx)
• EU Clinical Trials Register (https://
www.clinicaltrialsregister.eu/
Searching other resources
We searched the reference lists of all relevant publications we re-
trieved for other studies that had not been identified by the search
methods described above. We contacted manufacturers of dress-
ings and devices used to secure PVCs.
Data collection and analysis
Selection of studies
Two review authors (NM and JW) reviewed titles and abstracts
located by the search process independently. After obtaining full
copies of potentially relevant studies, the same two review authors
assessed study eligibility independently, according to the inclusion
and exclusion criteria. A third review author’s (CR) opinion would
have been sought had differences of opinion not been resolved by
consensus.
Data extraction and management
Two review authors (NM and JW) extracted data from all in-
cluded RCTs independently, using a pre-designed pro forma. One
review author (NM) entered data into Review Manager software
(RevMan 2012), and a second review author (JW) checked the
data for accuracy. If information regarding any part of the data was
unclear, we attempted to contact the study authors of the original
reports and asked them to provide further details. We included
trials published as duplicate reports (parallel publications) once,
using all associated trial reports to extract a maximal amount of
trial information, but ensuring that the trial data were not dupli-
cated in the review. We extracted the following information:
• participant characteristics and exclusions;
• type of dressing or securement device;
• setting;
• study dates;
• unit of investigation (participant or catheter);
• interventions;
• length of follow-up;
• information about ethics approval, consent and any
declared conflicts of interest; and
• outcomes.
Assessment of risk of bias in included studies
Independently, two review authors (NM and JW) assessed the
included studies for risk of bias using the ’Risk of bias’ tool outlined
in the Cochrane Handbook for Systematic Reviews of Interventions
(Higgins 2011).
This assessment of bias tool addresses seven specific domains (see
Appendix 2 for details), namely:
• sequence generation;
• allocation concealment;
• blinding of participants and personnel;
• blinding of outcome assessment;
• incomplete outcome data;
• selective outcome reporting;
• other possible problems that could put the study at risk of
bias, such as unequal numbers in the study groups or early
stopping of a trial.
Disagreements between the two review authors (NM and JW)
were discussed and resolved by consensus, or referral to a third
review author (CR). The overall assessment of the risk of bias is
presented in a ’Risk of bias’ summary figure, which displays all
judgements in a cross-tabulation of study by entry. This display
of internal validity indicates the weight the reader can give to the
results of any particular study.
Measures of treatment effect
For dichotomous outcomes, we calculated risk ratio (RR) plus
95% confidence intervals (CI). For continuous outcomes we cal-
culated the mean difference (MD) plus 95% CI. We planned
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to analyse any time-to-event data (e.g. time to development of
phlebitis) using hazard ratios and did not analyse time-to-event
data that were incorrectly presented as continuous data.
Unit of analysis issues
Ideally a studywould be designedwith patient-level randomisation
and analysis, and only one device per participant (adjustment for
clustering not necessary in this case), however, we expected to
find a number of studies that reported on multiple devices per
participant, randomised or analysed at device level, or both, and
unadjusted for clustering.
In such cases we planned to contact the study authors and attempt
to obtain:
• patient-level data or results;
• data or results for one device per participant; or
• device-level data,
and then perform multilevel regression to calculate the adjusted
effect. We would then combine the adjusted results in the meta-
analysis with those of patient-level trials (using the generic inverse
method), and perform sensitivity analyses (Higgins 2011). If we
were unsuccessful in obtaining the additional data required, then
we would exclude the study from the meta-analysis.
Dealing with missing data
We identified the missing data for each study and attempted to
contact the study authors to obtain the information necessary for
analysis. Where the data could not be obtained, we performed an
available-case analysis on the available data.We planned to address
the potential impact of missing data in the Discussion section
of the review. We also planned to explore the impact of missing
data on the study results with a sensitivity analysis that compared
the results from the analyses of study completers with those from
best-case and worst-case scenarios. In the best-case scenario, all
missing data from the treatment group were considered not to
indicate PVC failure, while those missing from the control group
were considered to indicate PVC failure. In the worst-case scenario
missing data from the treatment group were considered to indicate
PVC failure, while those missing from the control group were
considered not to indicate PVC failure.
Assessment of heterogeneity
Statistical heterogeneity was tested for by using the Chi2 test, with
significance set at a P value of less than0.10. In addition, the degree
of heterogeneity was investigated by calculating the I2 statistic
(Deeks 2011). This describes the percentage of the variability in
effect estimates that is due to heterogeneity rather than sampling
error (chance). A rough guide to interpretation is as follows: 0
to 40% might not be important; 30% to 60% may represent
moderate heterogeneity; 75% to 100% represents considerable
heterogeneity (Deeks 2011).The importance of the observed value
of I2 depends on firstly themagnitude and direction of effects, and
secondly the strength of evidence for heterogeneity (e.g. P value
from the Chi2 test, or a confidence interval for I2) (Deeks 2011).
Assessment of reporting biases
We planned that if there were 10 or more studies included in a
meta-analysis, we would assess for reporting bias by using a funnel
plot. If visual inspection of the symmetry of the funnel plot showed
that reporting bias was present, we planned to include a statement
in our results and a note of caution in our discussion. Where
possible, we also planned to access trial protocols and compare the
outcome measurements planned with those reported.
Data synthesis
We used ReviewManger to perform the meta-analysis of included
studies (RevMan 2012). If we had identified evidence of signifi-
cant heterogeneity (i.e. greater than 50%), we planned to explore
potential causes, and use a random-effects approach to the analy-
sis.
Subgroup analysis and investigation of heterogeneity
The following subgroup analyses were pre-specified in our proto-
col:
• Children (under 16 years of age) and adults.
• Continuous versus intermittent IV therapy.
• Additional bandaging versus dressing or securement device
alone.
Sensitivity analysis
We pre-specified in our protocol testing for the impact of the
following study characteristics in sensitivity analyses:
• adequate vs. inadequate concealment of allocation;
• size of studies (greater or fewer than 100 patients);
• follow-up period of less or more than 48 hours;
• missing data - best/worst case scenarios.
’Summary of findings’ table
We have presented the main results of the review in ’Summary of
findings’ tables. Summary of findings tables present key informa-
tion concerning the quality of the evidence, the magnitude of the
effects of the interventions examined, and the sum of the available
data for the main outcomes (Schünemann 2011a). ’Summary of
findings’ tables also include an overall grading of the evidence re-
lated to each of the main outcomes using the GRADE (Grading
of Recommendations Assessment, Development and Evaluation)
approach (Schünemann 2011b). The GRADE approach defines
the quality of a body of evidence with regard to the extent to which
one canbe confident that an estimate of effect or association is close
to the quantity of specific interest. Quality of a body of evidence
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involves consideration of within-trial risk of bias (methodological
quality), directness of evidence, heterogeneity, precision of effect
estimates and risk of publication bias (Schünemann 2011b). We
planned to present the following outcomes in ’Summary of find-
ings’ tables for all comparisons:
• proportion of failed catheters;
• time to catheter failure;
• adverse events.
R E S U L T S
Description of studies
See:Characteristics of included studies; Characteristics of excluded
studies.
Results of the search
We identified 56 references (see Figure 1). After reviewing titles
and abstracts, we eliminated 47 clearly irrelevant references. We
retrieved full text copies of the remaining nine potentially eligible
papers. We included six of these trials (Livesley 1993; Tripepi-
Bova 1997; Rodriguez 2002; Bausone-Gazda 2010; Chico-Padron
2011; Forni 2012), and excluded one trial (Machado 2005). Four
further trials are awaiting classification (Maki 1987; Machado
2008; Marsh 2014; Calvino Gunther 2014). We also identified
one trial on ClinicalTrials.gov but this was a prospective cohort
study.
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Figure 1. Flow diagram of included and excluded studies
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Included studies
Types of participants
We included six trials in this review, with a total of 1539 partici-
pants, and trial sizes ranging from 50 to 703. Two trials were con-
ducted in the USA (Tripepi-Bova 1997; Bausone-Gazda 2010),
two in Spain (Rodriguez 2002; Chico-Padron 2011), one in Italy
(Forni 2012), and one in England (Livesley 1993). All of the tri-
als were conducted in a single-centre, acute inpatient setting with
either paediatric only (Livesley 1993), adult and paediatric (Forni
2012) or adult only participants (Tripepi-Bova 1997; Rodriguez
2002; Bausone-Gazda 2010; Chico-Padron 2011). Among the
trials recruiting adults, the mean participant age ranged between
55 and 60 years. The majority of trials were conducted within a
10-year time frame, between 2000 and 2010 (Rodriguez 2002;
Bausone-Gazda 2010; Chico-Padron 2011; Forni 2012;), the
Tripepi-Bova 1997 trial was undertaken between 1994 and 1995.
It is unclear when the Livesley 1993 study was undertaken, but
results were published in 1993. Evidence of institutional ethics
approval was available for four of the trials (Tripepi-Bova 1997;
Bausone-Gazda 2010; Chico-Padron 2011; Forni 2012), and par-
ticipant consent in four trials (Livesley 1993; Bausone-Gazda
2010; Chico-Padron 2011; Forni 2012). Tripepi-Bova 1997 stated
that consent was not required, as both dressings were considered
non-experimental. One study acknowledged industry sponsorship
(Bausone-Gazda 2010).
Types of interventions
Four comparisons were reported in the included trials. The first
comparison was of transparent dressings compared with gauze
(Tripepi-Bova 1997; Rodriguez 2002; Chico-Padron 2011). The
intervention dressing used by Chico-Padron 2011 was described
simply as a transparent dressing, Rodriguez 2002 used a 3M™
Tegaderm™ Film Dressing and the transparent dressing in the
Tripepi-Bova 1997 study was Smith &Nephew’s Opsite. The sec-
ond comparison was of a bordered transparent dressing compared
to a securement device (Bausone-Gazda 2010), and the dressing
used in the intervention arm was 3M Tegaderm IV. The third
comparison was of a bordered transparent dressing (Veni-Guard
Breathable I.V. Dressing) assessed against tape (Livesley 1993),
and, the final comparison was of a transparent dressing - described
as a sterile dressing made of highly permeable polythene film, with
latex-free hypoallergenic adhesive - compared with sticking plaster
(Forni 2012).
Types of outcomes
For the first comparison, none of the three trials that compared
transparent dressings with gauze reported on either of our pri-
mary outcomes. Of the secondary outcomes for this comparison,
Chico-Padron 2011 measured dislodgement/accidental removal,
phlebitis, infiltration and cost; Rodriguez 2002 assessed phlebitis
and infiltration; and Tripepi-Bova 1997 provided data for dis-
lodgement/accidental removal, phlebitis and infiltration.
In the second comparison, the trial that compared a bordered
transparent dressing to a securement device provided data for
one of our primary outcomes - PVC failure, and for two sec-
ondary outcomes: dislodgement/accidental removal and phlebitis
(Bausone-Gazda 2010).
In the third comparison, a bordered transparent dressing compared
with tape, Livesley 1993 reported on the primary outcome of
PVC failure, as well as the secondary outcome of dislodgement/
accidental removal.
In the final comparison, a transparent sterile dressing with latex-
free hypoallergenic adhesive compared with sticking plaster, Forni
2012 assessed a number of our secondary outcomes: dislodgement/
accidental removal, phlebitis, infiltration and occlusion.
Data from three of the six included trials could be pooled (Tripepi-
Bova 1997; Rodriguez 2002; Chico-Padron 2011). When com-
paring transparent dressings with gauze, all three trials reported
the secondary outcomes of phlebitis and infiltration. Two of the
trials reported on the secondary outcomes of dislodgement/acci-
dental removal (Tripepi-Bova 1997; Chico-Padron 2011).
Excluded studies
We excluded one study (Machado 2005) that did not address the
research question (see Characteristics of excluded studies). Two
further trials (Maki 1987; Machado 2008) are awaiting further
information from authors (see Characteristics of studies awaiting
classification).
Risk of bias in included studies
Allocation
Sequence generation
Five of the investigators reported that they used computer gener-
ated randomisation (Livesley 1993; Tripepi-Bova 1997; Bausone-
Gazda 2010; Forni 2012) or a randomly generated number
list (Chico-Padron 2011). Rodriguez 2002 did not describe the
method used to generate the allocation sequence in the trial.
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Allocation concealment
Both Forni 2012 and Tripepi-Bova 1997 stated that sealed en-
velopes were used, but only Forni 2012 stated that the envelopes
were also opaque and numbered. The Bausone-Gazda 2010 trial
report stated that “randomization assignment was not provided
to the venous access device team nurse until the subject had been
assessed and the site determination had been made” but it was
unclear how the allocation details were concealed. Allocation con-
cealment was not described in reports of the other three trials
(Livesley 1993; Rodriguez 2002; Chico-Padron 2011).
Blinding
The appearance of dressings and securement devices were dissim-
ilar in all of the trials so it was not possible to blind participants or
personnel in any of the included trials. Outcome assessors were not
blinded to the intervention in any of the included trials (Livesley
1993; Tripepi-Bova 1997; Rodriguez 2002; Bausone-Gazda 2010;
Chico-Padron 2011; Forni 2012;). Two investigators had out-
come assessments conducted by ward nursing staff (Livesley 1993;
Tripepi-Bova 1997), another two did not identify clearly who per-
formed the outcome assessments (Rodriguez 2002; Chico-Padron
2011). Forni 2012 had assessments performed by research nurses
and Bausone-Gazda 2010 had assessments performed by the hos-
pitals Vascular Access Device team who also recruited the partici-
pants.
Incomplete outcome data
Four trials reported complete outcome data (Tripepi-Bova 1997;
Bausone-Gazda 2010; Chico-Padron 2011; Forni 2012). In the
Livesley 1993 study, the number of participants originally enrolled
in the trial was not stated but group numbers reported in the
results were quite unequal (69:86). This disparity may suggest
either post-randomisation exclusions, drop outs or a failure to
report (Livesley 1993). The Rodriguez 2002 trial was translated
for us from Spanish to English; it was unclear from the translation
whether data were incomplete and, if they were, whether losses
had been explained.
Selective reporting
Study protocols were not available for any of the included tri-
als (Livesley 1993; Tripepi-Bova 1997, Rodriguez 2002; Bausone-
Gazda 2010; Chico-Padron 2011; Forni 2012), so it was impos-
sible to determine if there was selective reporting bias.
Other potential sources of bias
Two trials had unequal numbers in the intervention groups
(Tripepi-Bova 1997; Chico-Padron 2011), and one trial stopped
early (Bausone-Gazda 2010). In this trial, which was manufac-
turer sponsored, the sample size was estimated to be 400 but only
302 patients were recruited. The reason provided for stopping
the trial early was “enrolment issues and the project timeline”
(Bausone-Gazda 2010).
Effects of interventions
See: Summary of findings for the main comparisonTransparent
dressing or gauze for securing peripheral venous catheters;
Summary of findings 2 Bordered transparent dressing versus
securement device for securing peripheral venous catheters;
Summary of findings 3 Bordered transparent dressing versus
tape for securing peripheral intravenous catheters; Summary of
findings 4Transparent dressing versus sticking plaster for securing
peripheral venous catheters
Transparent dressings compared with gauze (Analysis 1; SoF
Table 1)(3 trials)
Primary outcome: PVC failure due to IV complications
None of the trials in this comparison reported on PVC failure due
to IV complications.
Primary outcome: adverse events related to dressings and
securement devices
None of the trials in this comparison reported on adverse events.
Secondary outcome: dislodgement and accidental removal
Two trials (278 participants) reported on dislodgement/accidental
removal (Chico-Padron 2011; Tripepi-Bova 1997); the evidence
from these trials was assessed as very low quality; the method used
for group allocation was unclear and neither the personnel nor the
outcome assessors were blinded to group allocation. When results
were combined using a fixed-effect model (I2 0%), there were
significantly fewer instances of dislodgement/accidental removal
in the transparent dressing group (7/136) than in the gauze group
(19/142) (RR 0.40; 95% CI 0.17 to 0.92; Analysis 1.1)).
Secondary outcome: time to catheter failure
None of the trials in this comparison reported on time to catheter
failure.
Secondary outcome: phlebitis
Three trials (379 participants) at high risk of bias for at least two
domains of the risk of bias tool, reported phlebitis as an outcome
(Tripepi-Bova 1997; Rodriguez 2002; Chico-Padron 2011). There
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was no evidence of a difference in rates of phlebitis between trans-
parent dressings (16/184) and gauze (17/195) (RR 0.89; 95% CI
0.47 to 1.68; Analysis 1.2).
Secondary outcome: infiltration
Infiltration was reported in all three trials for this comparison
(379 participants) (Tripepi-Bova 1997; Rodriguez 2002; Chico-
Padron 2011). All trials were assessed as being at high risk of bias.
When results were combined, there was no evidence of a difference
between groups in rates of infiltration (transparent dressing 21/
184, gauze 29/195; RR 0.80; 95% CI 0.48 to 1.33; Analysis 1.3).
Secondary outcomes:
• occlusion;
• CRBSI with laboratory confirmation of catheter as the
source of infection;
• suspected CRBSI;
• entry site local infection;
• skin damage;
• cost;
• patient satisfaction;
• pain associated with dressing removal;
None of the trials in this comparison reported on these secondary
outcomes
For this comparison, heterogeneity was not an issue with I2 values
below 30% for all outcomes. However, with so few included trials
confidence intervals were wide (> 70%).
Bordered transparent dressing compared with a securement
device (Analysis 2; SoF Table 2)(1 trial)
Only one trial, judged to be at high risk of performance and de-
tection bias and at unclear risk for allocation concealment com-
pared bordered transparent dressings with a securement device
(Bausone-Gazda 2010). This trial included 302 participants, 150
in the bordered transparent dressing group and 152 in the secure-
ment device group, and reported four outcomes.
Primary outcome: PVC failure
There was no evidence of a difference between groups (bordered
transparent dressing 50/150 and securement device 59/152; RR
0.86; CI 0.64 to 1.16; Analysis 2.1) for PVC failure, where the
catheter has been removed due to IV complications or fell out.
Primary outcome: adverse events
Bausone-Gazda 2010 did not report on adverse events.
Secondary outcome: dislodgement and accidental removal
The bordered transparent dressing group had fewer instances
of dislodgement/accidental removal than the securement device
group (P value 0.008; bordered transparent dressing 2/150 and se-
curement device 14/152; RR 0.14; 95% CI 0.03 to 0.63; Analysis
2.2).
Secondary outcome: time to catheter failure
Bausone-Gazda 2010 reported time to catheter failure as a propor-
tion of failures occurring by 24, 48, 72 and 96 hours. There were
no reported differences between the bordered transparent and the
securement device groups for this measure.
Secondary outcome: phlebitis
The securement device group had fewer cases of phlebitis com-
pared with the bordered transparent dressing group (bordered
transparent dressing 8/150 and securement device 1/152;RR8.11;
CI 1.03 to 64.02; Analysis 2.3). Very wide confidence intervals for
this comparison indicate a very high level of uncertainty around
the effect size.
Secondary outcome: infiltration
Type of dressing showed no evidence of effect on the frequency
of infiltration between groups (bordered transparent dressing 21/
150 and securement device 27/152; RR 0.79; 95% CI 0.47 to
1.33; Analysis 2.4).
Secondary outcome: cost
Cost was reported to favour the bordered transparent dressing
(USD 5.65) when compared with the securement device (USD
7.56). NoP values or standard deviations were provided (Bausone-
Gazda 2010).
Secondary outcomes:
• occlusion;
• CRBSI with laboratory confirmation of catheter as the
source of infection;
• suspected CRBSI;
• entry site local infection;
• skin damage;
• cost;
• patient satisfaction;
• pain associated with dressing removal;
None of the trials in this comparison reported on these secondary
outcomes
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Bordered transparent dressing compared with tape
(Analysis 3; SoF Table 3)(1 trial)
One trial, which was assessed as being at high risk of bias (the
method used for group allocation was unclear and neither the per-
sonnel nor the outcome assessors were blinded to group alloca-
tion), compared a bordered transparent dressing and tape (Livesley
1993). This trial included 153 participants with a large disparity
in the number of participants in each group (68 in the bordered
transparent dressing group and 85 in the tape group). No explana-
tion was provided for the 20% difference in group numbers. Two
outcomes were assessed:
Primary outcome: PVC failure due to IV complications
PVC failure occurred less frequently in the tape group than the
bordered transparent dressing group (bordered transparent dress-
ing 25/68 and tape 17/85; RR1.84; 95%CI 1.09 to 3.11; Analysis
3.1.
Primary outcome: adverse events related to dressings and
securement devices
The Livesley 1993 trial did not report on adverse events.
Secondary outcome: dislodgement and accidental removal
There was no evidence of a difference in rates of dislodgement/
accidental removal for either securement method (bordered trans-
parent dressing 7/68 and tape 6/85; RR 1.46; 95% CI 0.51 to
4.14; Analysis 3.2).
Secondary outcome: time to catheter failure
Livesley 1993 reported that, “using survival analysis and plotting
the failure rate against duration, the difference between groups
failed to reach significance level”.
Secondary outcomes:
• phlebitis;
• infiltration;
• occlusion;
• CRBSI with laboratory confirmation of catheter as the
source of infection;
• suspected CRBSI;
• entry site local infection;
• skin damage;
• cost;
• patient satisfaction;
• pain associated with dressing removal;
None of the trials in this comparison reported on these secondary
outcomes
Transparent dressing compared with sticking plaster
(Analysis 4)(1 trial)
Forni 2012 was the only trial to compare a transparent dressing
with a sticking plaster. We contacted the author who provided
data for the first PVC only per patient. This trial was at high risk
of performance and detection bias and included 706 participants;
346 in the transparent dressing group and 357 in the sticking
plaster group.
Primary outcome: PVC failure due to IV complications
The Forni 2012 trial did not report on PVC failure due to IV
complications.
Primary outcome: adverse events related to dressings and
securement devices
Five cases of allergy were reported, three cases in the transparent
dressing group and two in the sticking plaster group. However,
information about how the allergic reaction presented and if fur-
ther follow-up management of the allergy was required was not
available.
Secondary outcome: dislodgement and accidental removal
There was no evidence of an effect difference on dislodgement/ac-
cidental removal when transparent dressings were compared with
sticking plaster (transparent dressing 22/346 and sticking plaster
17/357; RR 1.34; 95% CI 0.72 to 2.47; Analysis 4.1).
Secondary outcome: time to catheter failure
The Forni 2012 trial did not report on time to catheter failure.
Secondary outcome: phlebitis
There was no evidence of a difference in rates of phlebitis between
transparent dressings (25/346) and sticking plaster (29/357) how-
ever this comparison is underpowered (RR 0.89; 95% CI 0.53 to
1.49; Analysis 4.2).
Secondary outcome: infiltration
There was no evidence of a difference in rates of Infiltration be-
tween transparent dressings (34/346) and sticking plaster (41/357)
however this comparison is underpowered (RR 0.86; 95%CI 0.56
to 1.32; Analysis 4.3).
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Secondary outcome: occlusion
There was evidence of a difference in rates of occlusion between
transparent dressings (39/346) and sticking plaster (36/357) how-
ever this comparison is underpowered (RR 1.12; 95% CI 0.73 to
1.72; Analysis 4.4).
Secondary outcomes:
• CRBSI with laboratory confirmation of catheter as the
source of infection;
• suspected CRBSI;
• entry site local infection;
• skin damage;
• cost;
• patient satisfaction;
• pain associated with dressing removal;
None of the trials in this comparison reported on these secondary
outcomes.
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A D D I T I O N A L S U M M A R Y O F F I N D I N G S [Explanation]
Bordered transparent dressing versus securement device for securing peripheral venous catheters
Patient or population: Patients requiring a peripheral venous catheter
Settings: Hospital or community
Intervention: Bordered transparent dressing
Comparison: Securement device
Outcomes Illustrative comparative risks* (95% CI) Relative effect
(95% CI)
No of Participants
(studies)
Quality of the evidence
(GRADE)
Comments
Assumed risk Corresponding risk
Securement device Bordered transparent
dressing
PVC failure
Observation
Study population RR 0.86
(0.64 to 1.16)
302
(1 study)
⊕©©©
very low 1,2,3,4,5
388 per 1000 334 per 1000
(248 to 450)
Dislodgement/
accidental removal
Observation
Study population RR 0.14
(0.03 to 0.63)
302
(1 study)
⊕©©©
very low1,2,3,4,6
92 per 1000 13 per 1000
(3 to 58)
Phlebitis
Observation
Study population RR 8.11
(1.03 to 64.02)
302
(1 study)
⊕©©©
very low1,2,3,4,7
7 per 1000 53 per 1000
(7 to 421)
*The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% confidence interval) is based on the
assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).
CI: Confidence interval; RR: Risk ratio;
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GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our confidence in the estimate of effect.
Moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.
Low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.
Very low quality: We are very uncertain about the estimate.
1 Downgraded due to risk of bias (one level): Unblinded personnel and outcome assessors
2 Downgraded due to risk of bias (one level): Unclear if allocation to groups was blinded
3 Downgraded due to risk of bias (one level):The trial, which was manufacturer sponsored, was stopped early. In this trial, the sample
size was estimated to be 400 but only 302 patients were recruited
4Downgraded due to imprecision (one level): This outcome is reported in only one study
5 Downgraded due to imprecision (one level): The confidence interval crosses no difference so an increase of up to 63% in the rate of
PVC failure is possible
6 Downgraded due to imprecision (one level): The 95% confidence intervals ranged from 0.03 to 0.63
7 Downgraded due to imprecision (two levels): The 95% confidence intervals ranged from 1.03 to 64.02
1
9
D
e
v
ic
e
s
a
n
d
d
re
ssin
g
s
to
se
c
u
re
p
e
rip
h
e
ra
l
v
e
n
o
u
s
c
a
th
e
te
rs
to
p
re
v
e
n
t
c
o
m
p
lic
a
tio
n
s
(R
e
v
ie
w
)
C
o
p
y
rig
h
t
©
2
0
1
5
T
h
e
C
o
c
h
ra
n
e
C
o
lla
b
o
ra
tio
n
.
P
u
b
lish
e
d
b
y
Jo
h
n
W
ile
y
&
S
o
n
s,
L
td
.
Bordered transparent dressing versus tape for securing peripheral intravenous catheters
Patient or population: Patients requiring a peripheral venous catheter
Settings: Hospital or community
Intervention: Bordered transparent dressing
Comparison: Tape
Outcomes Illustrative comparative risks* (95% CI) Relative effect
(95% CI)
No of Participants
(studies)
Quality of the evidence
(GRADE)
Comments
Assumed risk Corresponding risk
Tape Bordered transparent
dressing
PVC failure
Observation
Study population* RR 1.84
(1.09 to 3.11)
153
(1 study)
⊕©©©
very low1,2,3,4,5
200 per 1000 368 per 1000
(218 to 622)
Dislodgement/
accidental removal
Observation
Study population RR 1.46
(0.51 to 4.14)
153
(1 study)
⊕©©©
very low1,2,3,4,6
71 per 1000 103 per 1000
(36 to 292)
Phlebitis This outcome was not reported Not estimable - See comment
*The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% confidence interval) is based on the
assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).
CI: Confidence interval; RR: Risk ratio;
GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our confidence in the estimate of effect.
Moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.
Low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.
Very low quality: We are very uncertain about the estimate.
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1 Downgraded due to risk of bias (one level): Unblinded personnel and outcome assessors
2 Downgraded due to risk of bias (one level): Unclear if allocation to groups was blinded
3 Downgraded due to risk of bias (one level): High risk of attrition bias
4 Downgraded due to imprecision (one level): This outcome is reported in only one study of 153
5Downgraded due to imprecision (two levels): The 95% confidence intervals ranged from 1.09 to 3.11
6 Downgraded due to imprecision (two levels): The confidence interval crosses no difference so an increase of almost 4 times the
incidence of dislodgement or accidental removal is possible
* Paediatic patients (excluding those at high risk e.g. intensive care, bone marrow transplant and metabolic unit patients)
xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx
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Transparent dressing versus sticking plaster for securing peripheral venous catheters
Patient or population: Patients requiring a peripheral venous catheter
Settings: Hospital or community
Intervention: Transparent dressing
Comparison: Sticking plaster
Outcomes Illustrative comparative risks* (95% CI) Relative effect
(95% CI)
No of Participants
(studies)
Quality of the evidence
(GRADE)
Comments
Assumed risk Corresponding risk
Sticking plaster Transparent dressing
PVC failure This outcome was not reported Not estimable - See comment
Dislodgement/
accidental removal
Observation
Study population RR 1.34
(0.72 to 2.47)
703
(1 study)
⊕©©©
very low1,2,3
48 per 1000 64 per 1000
(34 to 118)
Phlebitis
Observation
Study population RR 0.89
(0.53 to 1.49)
703
(1 study)
⊕⊕©©
low1,2,4
81 per 1000 72 per 1000
(43 to 121)
*The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% confidence interval) is based on the
assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).
CI: Confidence interval; RR: Risk ratio;
GRADE Working Group grades of evidence
High quality: Further research is very unlikely to change our confidence in the estimate of effect.
Moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.
Low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.
Very low quality: We are very uncertain about the estimate.
1 Downgraded due to risk of bias (one level): Unblinded personnel and outcome assessors2
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2 Downgraded due to imprecision (one level): This outcome is reported in only one study
3 Downgraded due to imprecision (two levels): The confidence interval crosses no difference so an increase of almost 2 1/5 time the
rate of dislodgement is possible
4 Downgraded due to imprecision (one level): The 95% confidence intervals ranged from 0.53 to 1.49
xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx
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D I S C U S S I O N
This systematic review compared the relative effectiveness of vari-
ous dressings and securement devices to prevent PVC failure due
to IV complications, such as dislodgement and accidental removal,
phlebitis and infiltration. Six RCTs were included: three compared
transparent dressings with gauze dressings (Tripepi-Bova 1997;
Rodriguez 2002; Chico-Padron 2011); one compared a bordered
transparent dressing with a securement device (Bausone-Gazda
2010); one compared a bordered transparent dressing with tape
(Livesley 1993); and one compared transparent dressings to stick-
ing plaster (Forni 2012).
Summary of main results
Primary outcome
Although the main purpose of PVC dressings and securement de-
vices is to prevent PVC failure, only two trials addressed this out-
come. One showed no evidence of a difference between a bordered
transparent dressing and a securement device (Bausone-Gazda
2010), while in the other trial (Livesley 1993), tape alone was
almost twice as effective in preventing catheter failure compared
with a bordered transparent dressing (RR 1.84; 95% CI 1.09 to
3.11; Analysis 3.1). However, in this trial, we were unable to de-
termine reasons for a disparity in the number of participants in
each group (68 bordered transparent dressing group and 85 tape
group), so the results are inconclusive.
Secondary outcomes
All of the trials reported on one or more of the individual com-
ponents of the composite primary outcome. Transparent dress-
ings, with or without a border, were more effective in prevent-
ing dislodgement or accidental removal compared with gauze or
a securement device (Tripepi-Bova 1997; Bausone-Gazda 2010;
Chico-Padron 2011), but transparent dressings showed no evi-
dence of benefit for any of the other secondary outcomes when
compared with tape or sticking plaster (Livesley 1993; Forni
2012).
Phlebitis was eight times more likely to occur when a bordered
transparent dressing was compared with a securement device (RR
8.11; 95% CI 1.03 to 64.02; Analysis 2.3). However, extremely
the wide confidence intervals for this result indicate that there is
a great deal of uncertainty about the effect size. No evidence of a
difference in phlebitis rates were shown when any other dressings
or devices were compared. Nor did any of the five trials measuring
infiltration show any evidence of effect; irrespective of the dressing
or device used to secure the PVC (Tripepi-Bova 1997; Rodriguez
2002; Bausone-Gazda 2010; Chico-Padron 2011; Forni 2012).
Similarly, catheter occlusion rates showed no evidence of a dif-
ference when transparent dressings were compared with sticking
plaster (Forni 2012). Cost was the only other outcome measured;
these results indicated that bordered transparent dressings were
a cheaper securement method compared to a securement device.
None of the single study comparisons was adequately powered
to detect differences, so there is a possibility that type two errors
could have occurred.
Overall completeness and applicability of
evidence
Dressings and securement devices for peripheral intravenous
catheters continue to evolve, with new products regularly coming
on to the market. A limited number of RCTs were available for
this review, so most of the comparisons in the review had only
one study contributing to the results. Consequently, some prod-
ucts in common use were not represented in this review. Another
restriction on the completeness and applicability of the review, is
that many of our primary and secondary outcomes were poorly re-
ported. For example, only two trials assessed our primary outcome
of PVC failure - the prevention of which is the main reason for ap-
plying a dressing or securement device. Moreover, other outcomes
of interest, such as entry site local infection, CRBSI and patient
satisfaction, were not reported at all. These omissions make the
selection of an effective securement device difficult for healthcare
providers. Finally, participants for this review were drawn largely
fromadult populations andwere predominately fromgeneralmed-
ical/surgical wards and orthopaedic specialties. Emergency depart-
ments and general cancer care areas, which are frequent users of
PVCs, were not included in this review. Additionally, the review
included only those patients admitted to acute hospitals settings,
consequently, the applicability of results to other settings, such as
community and rehabilitation facilities remains unknown.
Quality of the evidence
Limitations in study design and implementation
The quality of the evidence was assessed as very low, using the
GRADE approach (Schünemann 2011b). Risk of bias was as-
sessed using a seven-point judgement criteria table that included:
sequence generation, allocation concealment, blinding of partic-
ipants and personnel, blinding of outcome assessment, incom-
plete outcome reporting, selective outcome reporting and other
potential bias. Our assessments of risk of bias for a number of
these domains in all of the included trials demonstrated limita-
tions in study design, implementation or reporting; these have
been reported elsewhere in the review (Assessment of risk of bias
in included studies and summarised in Figure 2 and Figure 3). In
summary, only one trial reported sufficient information for us to
judge allocation concealment (Forni 2012). It was not possible to
24Devices and dressings to secure peripheral venous catheters to prevent complications (Review)
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blind personnel and participants to the intervention received, as
dressings were clearly different. This can be mitigated by blinding
of outcome assessment for at least some of the outcomes. In one
trial the participants also received a different PVC and extension
tubing according to their randomised dressing or securement de-
vice (Bausone-Gazda 2010), a co-intervention that may have had
an impact on the results. Livesley 1993 reported unequal num-
bers in the intervention groups with more participants receiving
a gauze dressing than a bordered transparent dressing, this may
indicate incomplete follow-up or incomplete reporting. One of
the included trials disclosed receiving manufacturer sponsorship
(Bausone-Gazda 2010). In all of the trials except one (Forni 2012),
the outcomes from the number of participants analysed matched
the number randomised. We could not determine whether this
was due to ’available case’ reporting or whether there were, indeed,
no losses to follow-up. In the one study where detailed recruitment
and follow-up data were available (Forni 2012), losses and reasons
for losses were similar across groups.
Figure 2. Risk of bias graph: review authors’ judgements about each risk of bias item presented as
percentages across all included studies
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Figure 3. Risk of bias summary: review authors’ judgements about each risk of bias item for each included
study
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Indirectness of evidence
In the only comparison where we were able to synthesise evi-
dence from more than one trial, there was reasonable conformity
between intervention products. These were all transparent dress-
ings, that came from different manufacturers, claimed different
attributes, and for which the results were published over a wide
time-frame (1997 to 2011). However, the problem of indirect-
ness occurs when head-to-head comparisons are made in different
studies between one intervention (e.g. a transparent dressing) and
alternative controls (e.g. in this case, a securement device, tape,
gauze and sticking plaster). In such cases, it is difficult to know
the relative effectiveness of say, tape against a securement device.
Unexplained heterogeneity or inconsistency of results
In all of the pooled outcomes, heterogeneity was less than 30%
indicating that, although populations and interventions varied
slightly across studies, they were similar enough to combine re-
sults.
Imprecision of results
Confidence intervals were wide in the pooled outcomes, but few
studies were included and sample sizes were small. Imprecise re-
sults may reflect differences in intervention products and outcome
definitions. Confidence intervals were also wide in the single stud-
ies that showed evidence of effect. In the Bausone-Gazda 2010
trial, for the ’dislodgement’ outcome the CIs lay between 0.03 and
0.60, and for phlebitis between 1.04 and 67.97. When Livesley
1993 assessed PVC failure it was shown to be almost twice as high
in the bordered transparent dressing group when compared with
the tape group, but the CIs ranged between 1.09 and 3.11. Again,
the uncertainty around the effect sizes for these outcomes suggests
that further research is required to increase the level of certainty
around the results.
Publication bias
We feel confident that our comprehensive electronic searches iden-
tified all existing, published RCTs addressing the review question,
helping to limit bias in the review process. One manufacturer-
sponsored, observational study, comparing two different catheter
stabilising systems was identified through Clinical trials.com. The
trial was completed in 2013 but results have not been published.
The scant contribution of the six included trials, in the face of
such wide use and evolving products for PVC stabilisation, seems
unusual. This may or may not indicate publication bias. There
were fewer than 10 studies, so we did not construct a funnel plot.
Potential biases in the review process
Clearly described procedures were followed to prevent potential
bias in the review process. A careful literature search was con-
ducted, and the methods used are transparent and reproducible.
None of the review authors has reported a conflict of interest.
Agreements and disagreements with other
studies or reviews
One other systematic review has addressed a similar topic (
Hoffmann 1992). The review was published before any RCTs in
this area were available, so the inclusion criteria for the review
were wide (abstracts, letters, observational studies). The focus of
the review was to a compare transparent polyurethane dressing
with a gauze dressing for peripheral catheters. Two of the out-
comes assessed in the Hoffmann 1992 review were the same as
ours (phlebitis and infiltration), so we were able to compare re-
sults. Although the inclusion criteria were quite different in the
Hoffman review, our results for these outcomes were in agreement
and no between group differences were found for either phlebitis
or infiltration. Similarly, in an earlier, quasi-RCT of 598 partic-
ipants, published by the same author, no statistically significant
differences were found in the rate of phlebitis between a trans-
parent polyurethane group and a cotton gauze group (Hoffmann
1988).
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
There is no strong evidence to suggest that any one dressing or
securement product for peripheral catheters is more effective than
any other dressing. We found limited evidence that catheters were
less likely to fail due to dislodgement or accidental removal when
a transparent dressing was used, compared with gauze. Other pos-
itive outcomes, favouring one dressing over another, were based
on single studies, so further trials are required to support their
findings. All of the included trials were small, had either high or
unclear risk of bias for one or more of the quality elements we as-
sessed, andwide confidence intervals, indicating that further RCTs
are necessary.
Implications for research
Products included in this review were limited, as were the out-
comes assessed. There is a need for suitably powered, high quality
trials to evaluate the newer, high use products and novel - but
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expensive - securement methods, such as surgical grade glue. Fol-
lowing items in the CONSORT statement when planning and
reporting future trials, would provide more transparency for those
assessing the quality of the studies. Important outcomes such as
catheter-related bloodstream infection, entry site local infection,
skin damage and the patient’s satisfaction with the product were
not available for assessment in this review, but should be included
in future studies. Given the large cost difference between differ-
ent dressings and securement devices, we believe it is important
to include a planned economic analysis, including the number of
dressing changes required and staff time involved. This would en-
able decision makers to make rational and cost effective choices
when purchasing dressings and devices for peripheral catheter se-
curement.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Bausone-Gazda 2010
Methods Study design: single-centre RCT
Method of randomisation: computer generated
Concealment of allocation: allocation concealed until the subject had been assessed
and site determination made
Participants Country: USA
Number: 302 medical-surgical patients with an anticipated 96-hour need for a PVC.
Bordered transparent dressings were applied to 150 participants and a securement device
was used for 152 participants.
Age: bordered transparent group: mean 60 years; securement device group: mean 60.8
years
Sex (female:male): bordered transparent group: 84:66; securement device group: 92:60
Inclusion criteria: at least 18 years of age; inpatients expected to require a PVC for 96
hours; available insertion site on the hand or arm; demonstrate cooperation with medical
devices and/or treatments; able to provide consent.
Exclusion criteria: current participants or those who have already participated in the
study; PVC site located below an old infusion site or at an area of flexion; documented
sensitivity to medical adhesive products; dermatitis, burns, or tattoos at or near the
insertion site; diaphoretic at the time of catheter insertion; require application of topical
antibiotics or ointments under the dressing; PVC site that requires a gauze pad or a
tackifier; pregnant; conditions that in the opinion of the investigator of staff nurse would
make the patient unsuitable for enrolment in the study
Interventions Bordered transparent group: insertion of a BD Nexiva Closed IV Catheter System
with a built-in stabilization platform and extension tubing with 2 split-septum access
ports. The insertion site was covered with a 3M Tegaderm IV securement dressing and
extension tubing secured to the skin
Securement device group: insertion of a non winged B Braun Introcan Safety Catheter
to which an extension tubing was attached. After placement a transparent dressing was
used to cover the insertion site, and the extension tubing was secured to the skin
Outcomes Primary outcome: PVC failure - where PVC was removed due to IV complications or
fell out
Secondary outcome: dislodgement/accidental removal, phlebitis (as defined by the trial
investigator)
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
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Bausone-Gazda 2010 (Continued)
Random sequence generation (selection
bias)
Low risk Quotation: “Subjects were randomised us-
ing a computer-generated randomisation
process”
Allocation concealment (selection bias) Unclear risk Quotation: “The randomisation assign-
ment was not provided to the VAD nurse
until the subject had been assessed and the
site determination had been made”
Blinding (performance bias and detection
bias)
Participants
Low risk Comment: blinding of the participants was
not possible due to the type of intervention
(the 2 different securement methods had
different appearances). However, this was
unlikely to have influenced the outcome
Blinding (performance bias and detection
bias)
Personnel
High risk Comment: blinding of personnel was not
possible due to the type of intervention (the
2 different securement methods had differ-
ent appearances)
Blinding (performance bias and detection
bias)
Outcome assessor
High risk Quotation: “When the catheter-stabiliza-
tion system was removed, the VAD nurse
recorded the reason for removal, ease of re-
moval, any presence of adhesive residue on
skin or catheter, skin redness or blisters, and
the VAD nurse’s overall satisfaction with
the catheter and stabilization device”
Comment: blinding of outcome assessor
was not possible due to the type of inter-
vention (the 2 different securement meth-
ods had different appearances)
Incomplete outcome data (attrition bias)
All outcomes
Low risk Comment: number analysed matched
number randomised
Selective reporting (reporting bias) Low risk Comment: although the protocol was not
available, expected outcomes for this com-
parison were reported
Other bias High risk Comment: the trial was stopped early. One
author was an employee of the company
manufacturing the intervention product
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Chico-Padron 2011
Methods Study design: single-centre RCT
Method of randomisation: randomly generated number list
Concealment of allocation: not stated
Participants Country: Spain
Number: 50 patients admitted to general surgical ward and coronary intensive care
unit. A transparent dressing was applied to 29 participants’ PVC site and gauze to 21
participants’.
Age: transparent dressing group: mean 56 years; gauze group: mean 57 years
Sex: not reported
Inclusion criteria: not reported
Exclusion criteria: not reported
Interventions Transparent dressing group: catheter fixed to skin with sterile strip, transparent dressing
applied
Gauze group: catheter fixed to skin with sterile strip, gauze dressing applied
Outcomes Secondary outcome: dislodgement/accidental removal, phlebitis (as defined by the trial
investigator), infiltration, cost
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quotation: “used a randomly generated
numbers list for assignment”
Allocation concealment (selection bias) Unclear risk Comment: not described
Blinding (performance bias and detection
bias)
Participants
Low risk Comment: blinding of the participants was
not possible due to the type of intervention
(the 2 different securement methods had
different appearances). However, this was
unlikely to have influenced the outcome
Blinding (performance bias and detection
bias)
Personnel
High risk Comment: blinding of personnel was not
possible due to the type of intervention (the
2 different securement methods had differ-
ent appearances)
Blinding (performance bias and detection
bias)
Outcome assessor
High risk Comment: blinding of outcome assessor
was not possible due to the type of inter-
vention (the 2 different securement meth-
ods had different appearances)
Incomplete outcome data (attrition bias)
All outcomes
Low risk Comment: all recruited patients accounted
for in results
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Chico-Padron 2011 (Continued)
Selective reporting (reporting bias) Low risk Comment: protocol not available, but out-
comes stated in design were reported
Other bias Unclear risk Comment: unequal number of participants
allocated to groups. Participants may have
had a catheter in situ when assigned to a
group and consequently, some of the out-
comes may have been due to the previous
dressing
Forni 2012
Methods Study design: single-centre RCT
Method of randomisation: computer generated
Concealment of allocation: opaque envelopes were used according to the sequence
indicated by the computer generated list
Participants Country: Italy
Number: 703 paediatric and adult patients with orthopedic/traumatological problems
and orthopedic oncological diseases. A transparent dressing was applied to 346 partici-
pants’ PVC site and sticking plaster to 357 participants’.
Age: transparent dressing group: mean 54.9 years; sticking plaster group: mean 55.4
years
Sex (female:male): unable to extract
Inclusion criteria: required PVC for at least 24 hours; informed consent
Exclusion criteria: a known allergy to one of the 2 plasters/dressings; undergoing stem
cell transplantation; treated in a day-surgery setting; an allergy to chlorhexidine 0.5%
in alcohol (skin preparation); under intensive short-term observation; PVC placed at
another hospital
Interventions Transparent dressing group: transparent sterile dressing made of highly permeable
polythene film, with latex free hypoallergenic adhesive
Sticking plaster group: non sterile, elastic, vellum-like polyester lined sticking plaster
with hypoallergenic adhesive
Outcomes Secondary outcome: dislodgement/accidental removal, phlebitis (as defined by the trial
investigator), infiltration, occlusion
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quotation: ”A randomised list in blocks of
ten was generated by a computer”
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Forni 2012 (Continued)
Allocation concealment (selection bias) Low risk Opaque envelopes were used to contain the
type of securement device according to the
sequence indicated by the list
Blinding (performance bias and detection
bias)
Participants
Low risk Comment: blinding of the participants was
not possible due to the type of intervention
(the 2 different securement methods had
different appearances). However, this was
unlikely to have influenced the outcome
Blinding (performance bias and detection
bias)
Personnel
High risk Comment: blinding of personnel was not
possible due to the type of intervention (the
2 different securement methods had differ-
ent appearances)
Blinding (performance bias and detection
bias)
Outcome assessor
High risk Comment: blinding of outcome assessor
was not possible due to the type of inter-
vention (the 2 different securement meth-
ods had different appearances)
Incomplete outcome data (attrition bias)
All outcomes
Low risk Comment: all randomised catheters were
reported in the outcome tables. Missing
outcome data balanced in numbers across
intervention groups, with similar reasons
for missing data across groups
Selective reporting (reporting bias) Low risk Comment: no protocol was available how-
ever expected outcomes were reported
Other bias Low risk
Livesley 1993
Methods Study design: single-centre RCT
Method of randomisation: computer generated
Concealment of allocation: not described
Participants Country: England
Number: 155 paediatric patients form a paediatric university teaching hospital (exclud-
ing intensive care, metabolic unit and bone marrow transplant unit). A bordered trans-
parent dressing was applied to 69 participants’ PVC site and tape to 86 participants’
Age: mean age not provided
Sex: not provided
Inclusion criteria: children being cannulated for the first time for the present admission;
informed consent from parent or guardian
Exclusion criteria: not described
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Livesley 1993 (Continued)
Interventions Bordered transparent dressing group: the PVC was secured with a sterile dressing,
Venigard®, and a ’T’-piece extension set with a Luer-lock was attached between the
cannula hub and extension set or administration set
Tape: non sterile tape was used to secure the cannula with an extension or administration
set fixed to the hub of the cannula
Outcomes Primary outcome: PVC failure - where PVC was removed due to IV complications or
fell out
Secondary outcome: dislodgement/accidental removal
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quotation: “a computer-generated num-
bers list to randomise children prospec-
tively”
Allocation concealment (selection bias) Unclear risk Comment: not stated
Blinding (performance bias and detection
bias)
Participants
Low risk Comment: blinding of the participants was
not possible due to the type of intervention
(the 2 different securement methods had
different appearances). However, this was
unlikely to have influenced the outcome
Blinding (performance bias and detection
bias)
Personnel
High risk Comment: blinding of personnel was not
possible due to the type of intervention (the
2 different securement methods had differ-
ent appearances)
Blinding (performance bias and detection
bias)
Outcome assessor
High risk Comment: blinding of outcome assessor
was not possible due to the type of inter-
vention (the 2 different securement meth-
ods had different appearances)
Incomplete outcome data (attrition bias)
All outcomes
High risk Comment: number enrolled not stated.
Unequal number in groups suggests drop
outs or failure to report
Selective reporting (reporting bias) Low risk Comment: protocol unavailable. Only
catheter failure and accidental removal were
mentioned in themethods section andboth
were reported in results
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Livesley 1993 (Continued)
Other bias Low risk Funding was provided in part by a manu-
facturer of Intravenous Infusion machines,
but these product were not included in the
study
Rodriguez 2002
Methods Study design: single-centre RCT
Method of randomisation: not described
Concealment of allocation: not described
Participants Country: Spain
Number: 100 patients participated in this trial, 47 participants had a transparent dressing
applied to their PVC site and 53 participants had a gauze dressing
Age: transparent dressing group: mean 63.69 years; gauze group: mean 59.44 years
Sex (female:male): transparent dressing group:13:34; gauze group: 20:33
Inclusion criteria: need for a PVC on the forearm or back of hand
Exclusion criteria: need for a CVL; PVC in a location other than forearm or back of
the hand; emergency patients; patients not part of trial at catheterization; patients with
allergies requiring a different type of adhesive dressing
Interventions Transparent dressing group: 3M Tegaderm transparent™
Gauze group: gauze dressing
Outcomes Secondary outcome: phlebitis (as defined by the trial investigator), infiltration
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Comment: not stated
Allocation concealment (selection bias) Unclear risk Comment: not stated
Blinding (performance bias and detection
bias)
Participants
Low risk Comment: blinding of the participants was
not possible due to the type of intervention
(the 2 different securement methods had
different appearances). However, this was
unlikely to have influenced the outcome
Blinding (performance bias and detection
bias)
Personnel
High risk Comment: blinding of personnel was not
possible due to the type of intervention (the
2 different securement methods had differ-
ent appearances)
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Rodriguez 2002 (Continued)
Blinding (performance bias and detection
bias)
Outcome assessor
High risk Comment: blinding of outcome assessor
was not possible due to the type of inter-
vention (the 2 different securement meth-
ods had different appearances)
Incomplete outcome data (attrition bias)
All outcomes
Low risk Comment: all recruited patient were ac-
counted for in results
Selective reporting (reporting bias) Low risk Comment: protocol unavailable. Phlebitis
and infiltration were mentioned in the
methods section and both were reported in
results
Other bias Unclear risk Comment: unable to extract this data
Tripepi-Bova 1997
Methods Study design: single-centre RCT
Method of randomisation: computer generated
Concealment of allocation: sealed envelopes
Participants Country: USA
Number: 229 patients from 6 units (2 medical cardiology, surgical cardiology, general
internal medicine, orthopedic and neurological intensive care). A transparent dressing
was applied to 108 participants’ PVC site and gauze to 121 participants’
Age: not stated
Sex: not stated
Inclusion criteria: not stated
Exclusion criteria: not stated
Interventions Transparent dressing: Opsite®(Smith & Nephew, Quebec, Canada) applied directly
over the insertion site. Tape applied to secure the IV tubing
Gauze:Mirasorb ®sponges (5 cm x 5 cm; Johnson & Johnson Medical Inc, Arlington,
Texas) applied directly over the insertion site. Tape applied to secure the IV tubing
Outcomes Secondary outcome: dislodgement/accidental removal, phlebitis (as defined by the trial
investigator), infiltration
Notes
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quotation: “Eligible patients were assigned
randomly, bymeans of computer generated
randomised codes in sealed envelopes”
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Tripepi-Bova 1997 (Continued)
Allocation concealment (selection bias) Unclear risk Comment: no mention that the envelopes
were opaque. There was insufficient infor-
mation about the concealment provided to
make a judgement of risk of bias
Blinding (performance bias and detection
bias)
Participants
Low risk Comment: blinding of the participants was
not possible due to the type of intervention
(the 2 different securement methods had
different appearances). However, this was
unlikely to have influenced the outcome
Blinding (performance bias and detection
bias)
Personnel
High risk Comment: blinding of personnel was not
possible due to the type of intervention (the
2 different securement methods had differ-
ent appearances)
Blinding (performance bias and detection
bias)
Outcome assessor
High risk Comment: blinding of outcome assessor
was not possible due to the type of inter-
vention (the 2 different securement meth-
ods had different appearances)
Incomplete outcome data (attrition bias)
All outcomes
Low risk Comment: all recruited patients accounted
for in results
Selective reporting (reporting bias) Low risk Comment: no protocol was available how-
ever expected outcomes were reported
Other bias Unclear risk Comment: unclear due to the unequal
numbers in each group
Abbreviations
CVL = central venous line
PVC = peripheral venous catheter
RCT = randomised controlled trial
Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Machado 2005 Did not address the research question
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Characteristics of studies awaiting assessment [ordered by study ID]
Calvino Gunther 2014
Methods Single centre, 2-arm RCT
Participants Patients > 18 years admitted to an intensive care unit
Interventions 3Mtm IV Advanced (intervention), 3Mtm HP (control for 9 months) or Smith and Nephew IV3000tm (control for
seven months)
Outcomes Post-insertion complications, mean number of complication per patient, time of occurrence, life span of catheters,
number of disrupted dressings, and tolerance
Notes Awaiting assessment
Machado 2008
Methods RCT
Participants Children aged 0-12 years
Interventions Sterile gauze (intervention), transparent dressing (intervention) and adhesive tape (control)
Outcomes Unclear
Notes Awaiting response from author
Maki 1987
Methods RCT
Participants Adults over 18 years
Interventions Eight ply fine mesh sterile gauze and tape (intervention), polyurethane transparent adhesive dressing (intervention),
transparent dressing with a poly-N-vinyl-pyrolidone-acrylated adhesive that contained 2% titratable iodine iodophor
antiseptic (intervention) and sterile gauze replaced every 48 hours (control)
Outcomes Unclear
Notes Awaiting response from author
Marsh 2014
Methods Single centre, 4-arm RCT
Participants Patients in an acute hospital who required a peripheral venous catheter
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Marsh 2014 (Continued)
Interventions Intervention 1: Hystoacryl glue and a standard polyurethane dressing (SPU); Intervention 2: a bordered polyurethane
dressing; Intervention 3: a sutureless securement device and SPU; Control: SPU
Outcomes Peripheral intravenous catheter failure.
Notes Awaiting assessment
Abbreviation
RCT = randomised controlled trial
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D A T A A N D A N A L Y S E S
Comparison 1. Transparent dressing versus gauze
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Dislodgement/accidental
removal
2 278 Risk Ratio (M-H, Fixed, 95% CI) 0.40 [0.17, 0.92]
2 Phlebitis 3 379 Risk Ratio (M-H, Fixed, 95% CI) 0.89 [0.47, 1.68]
3 Infliltration 3 379 Risk Ratio (M-H, Fixed, 95% CI) 0.80 [0.48, 1.33]
Comparison 2. Bordered transparent dressing versus securement device
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 PVC failure 1 302 Risk Ratio (M-H, Fixed, 95% CI) 0.86 [0.64, 1.16]
2 Dislodgement/accidental
removal
1 302 Risk Ratio (M-H, Fixed, 95% CI) 0.14 [0.03, 0.63]
3 Phlebitis 1 302 Risk Ratio (M-H, Fixed, 95% CI) 8.11 [1.03, 64.02]
4 Infiltration 1 302 Risk Ratio (M-H, Fixed, 95% CI) 0.79 [0.47, 1.33]
Comparison 3. Bordered transparent dressing versus tape
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 PVC failure 1 153 Risk Ratio (M-H, Fixed, 95% CI) 1.84 [1.09, 3.11]
2 Dislodgement/accidental
removal
1 153 Risk Ratio (M-H, Fixed, 95% CI) 1.46 [0.51, 4.14]
Comparison 4. Transparent dressing versus sticking plaster
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Dislodgement/accidental
removal
1 703 Risk Ratio (M-H, Fixed, 95% CI) 1.34 [0.72, 2.47]
2 Phlebitis 1 703 Risk Ratio (M-H, Fixed, 95% CI) 0.89 [0.53, 1.49]
3 Infliltration 1 703 Risk Ratio (M-H, Fixed, 95% CI) 0.86 [0.56, 1.32]
4 Occlusion 1 703 Risk Ratio (M-H, Fixed, 95% CI) 1.12 [0.73, 1.72]
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Analysis 1.1. Comparison 1 Transparent dressing versus gauze, Outcome 1 Dislodgement/accidental
removal.
Review: Devices and dressings to secure peripheral venous catheters to prevent complications
Comparison: 1 Transparent dressing versus gauze
Outcome: 1 Dislodgement/accidental removal
Study or subgroup Transparent Gauze Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Chico-Padron 2011 1/29 1/21 6.4 % 0.72 [ 0.05, 10.93 ]
Tripepi-Bova 1997 6/107 18/121 93.6 % 0.38 [ 0.16, 0.91 ]
Total (95% CI) 136 142 100.0 % 0.40 [ 0.17, 0.92 ]
Total events: 7 (Transparent), 19 (Gauze)
Heterogeneity: Chi2 = 0.20, df = 1 (P = 0.65); I2 =0.0%
Test for overall effect: Z = 2.14 (P = 0.032)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours transparent Favours gauze
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Analysis 1.2. Comparison 1 Transparent dressing versus gauze, Outcome 2 Phlebitis.
Review: Devices and dressings to secure peripheral venous catheters to prevent complications
Comparison: 1 Transparent dressing versus gauze
Outcome: 2 Phlebitis
Study or subgroup Transparent Gauze Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Chico-Padron 2011 8/29 5/21 33.9 % 1.16 [ 0.44, 3.04 ]
Rodriguez 2002 6/47 8/53 44.0 % 0.85 [ 0.32, 2.26 ]
Tripepi-Bova 1997 2/108 4/121 22.1 % 0.56 [ 0.10, 3.00 ]
Total (95% CI) 184 195 100.0 % 0.89 [ 0.47, 1.68 ]
Total events: 16 (Transparent), 17 (Gauze)
Heterogeneity: Chi2 = 0.59, df = 2 (P = 0.74); I2 =0.0%
Test for overall effect: Z = 0.36 (P = 0.72)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours transparent Favours gauze
Analysis 1.3. Comparison 1 Transparent dressing versus gauze, Outcome 3 Infliltration.
Review: Devices and dressings to secure peripheral venous catheters to prevent complications
Comparison: 1 Transparent dressing versus gauze
Outcome: 3 Infliltration
Study or subgroup Transparent Gauze Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Chico-Padron 2011 2/29 0/21 2.0 % 3.67 [ 0.19, 72.63 ]
Rodriguez 2002 0/47 4/53 14.9 % 0.13 [ 0.01, 2.26 ]
Tripepi-Bova 1997 19/108 25/121 83.1 % 0.85 [ 0.50, 1.46 ]
Total (95% CI) 184 195 100.0 % 0.80 [ 0.48, 1.33 ]
Total events: 21 (Transparent), 29 (Gauze)
Heterogeneity: Chi2 = 2.63, df = 2 (P = 0.27); I2 =24%
Test for overall effect: Z = 0.86 (P = 0.39)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours transparent Favours gauze
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Analysis 2.1. Comparison 2 Bordered transparent dressing versus securement device, Outcome 1 PVC
failure.
Review: Devices and dressings to secure peripheral venous catheters to prevent complications
Comparison: 2 Bordered transparent dressing versus securement device
Outcome: 1 PVC failure
Study or subgroup Bordered transparent Securement device Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Bausone-Gazda 2010 50/150 59/152 100.0 % 0.86 [ 0.64, 1.16 ]
Total (95% CI) 150 152 100.0 % 0.86 [ 0.64, 1.16 ]
Total events: 50 (Bordered transparent), 59 (Securement device)
Heterogeneity: not applicable
Test for overall effect: Z = 0.99 (P = 0.32)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours b-transparent Favours securement device
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Analysis 2.2. Comparison 2 Bordered transparent dressing versus securement device, Outcome 2
Dislodgement/accidental removal.
Review: Devices and dressings to secure peripheral venous catheters to prevent complications
Comparison: 2 Bordered transparent dressing versus securement device
Outcome: 2 Dislodgement/accidental removal
Study or subgroup Bordered transparent Securement device Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Bausone-Gazda 2010 2/150 14/152 100.0 % 0.14 [ 0.03, 0.63 ]
Total (95% CI) 150 152 100.0 % 0.14 [ 0.03, 0.63 ]
Total events: 2 (Bordered transparent), 14 (Securement device)
Heterogeneity: not applicable
Test for overall effect: Z = 2.59 (P = 0.0097)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours b-transparent Favours securement device
Analysis 2.3. Comparison 2 Bordered transparent dressing versus securement device, Outcome 3 Phlebitis.
Review: Devices and dressings to secure peripheral venous catheters to prevent complications
Comparison: 2 Bordered transparent dressing versus securement device
Outcome: 3 Phlebitis
Study or subgroup Bordered transparent Securement device Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Bausone-Gazda 2010 8/150 1/152 100.0 % 8.11 [ 1.03, 64.02 ]
Total (95% CI) 150 152 100.0 % 8.11 [ 1.03, 64.02 ]
Total events: 8 (Bordered transparent), 1 (Securement device)
Heterogeneity: not applicable
Test for overall effect: Z = 1.98 (P = 0.047)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours b-transparent Favours securement device
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Analysis 2.4. Comparison 2 Bordered transparent dressing versus securement device, Outcome 4
Infiltration.
Review: Devices and dressings to secure peripheral venous catheters to prevent complications
Comparison: 2 Bordered transparent dressing versus securement device
Outcome: 4 Infiltration
Study or subgroup Bordered transparent Securement device Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Bausone-Gazda 2010 21/150 27/152 100.0 % 0.79 [ 0.47, 1.33 ]
Total (95% CI) 150 152 100.0 % 0.79 [ 0.47, 1.33 ]
Total events: 21 (Bordered transparent), 27 (Securement device)
Heterogeneity: not applicable
Test for overall effect: Z = 0.89 (P = 0.37)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours b-transparent Favours securement device
Analysis 3.1. Comparison 3 Bordered transparent dressing versus tape, Outcome 1 PVC failure.
Review: Devices and dressings to secure peripheral venous catheters to prevent complications
Comparison: 3 Bordered transparent dressing versus tape
Outcome: 1 PVC failure
Study or subgroup Bordered transparent Tape Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Livesley 1993 25/68 17/85 100.0 % 1.84 [ 1.09, 3.11 ]
Total (95% CI) 68 85 100.0 % 1.84 [ 1.09, 3.11 ]
Total events: 25 (Bordered transparent), 17 (Tape)
Heterogeneity: not applicable
Test for overall effect: Z = 2.26 (P = 0.024)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours b-transparent Favours tape
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Analysis 3.2. Comparison 3 Bordered transparent dressing versus tape, Outcome 2
Dislodgement/accidental removal.
Review: Devices and dressings to secure peripheral venous catheters to prevent complications
Comparison: 3 Bordered transparent dressing versus tape
Outcome: 2 Dislodgement/accidental removal
Study or subgroup Bordered transparent Tape Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Livesley 1993 7/68 6/85 100.0 % 1.46 [ 0.51, 4.14 ]
Total (95% CI) 68 85 100.0 % 1.46 [ 0.51, 4.14 ]
Total events: 7 (Bordered transparent), 6 (Tape)
Heterogeneity: not applicable
Test for overall effect: Z = 0.71 (P = 0.48)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours b-transparent Favours tape
Analysis 4.1. Comparison 4 Transparent dressing versus sticking plaster, Outcome 1
Dislodgement/accidental removal.
Review: Devices and dressings to secure peripheral venous catheters to prevent complications
Comparison: 4 Transparent dressing versus sticking plaster
Outcome: 1 Dislodgement/accidental removal
Study or subgroup Transparent Sticking plaster Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Forni 2012 22/346 17/357 100.0 % 1.34 [ 0.72, 2.47 ]
Total (95% CI) 346 357 100.0 % 1.34 [ 0.72, 2.47 ]
Total events: 22 (Transparent), 17 (Sticking plaster)
Heterogeneity: not applicable
Test for overall effect: Z = 0.92 (P = 0.36)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours transparent Favours sticking plaster
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Analysis 4.2. Comparison 4 Transparent dressing versus sticking plaster, Outcome 2 Phlebitis.
Review: Devices and dressings to secure peripheral venous catheters to prevent complications
Comparison: 4 Transparent dressing versus sticking plaster
Outcome: 2 Phlebitis
Study or subgroup Transparent Sticking plaster Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Forni 2012 25/346 29/357 100.0 % 0.89 [ 0.53, 1.49 ]
Total (95% CI) 346 357 100.0 % 0.89 [ 0.53, 1.49 ]
Total events: 25 (Transparent), 29 (Sticking plaster)
Heterogeneity: not applicable
Test for overall effect: Z = 0.45 (P = 0.66)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours transparent Favours sticking plaster
Analysis 4.3. Comparison 4 Transparent dressing versus sticking plaster, Outcome 3 Infliltration.
Review: Devices and dressings to secure peripheral venous catheters to prevent complications
Comparison: 4 Transparent dressing versus sticking plaster
Outcome: 3 Infliltration
Study or subgroup Transparent Sticking plaster Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Forni 2012 34/346 41/357 100.0 % 0.86 [ 0.56, 1.32 ]
Total (95% CI) 346 357 100.0 % 0.86 [ 0.56, 1.32 ]
Total events: 34 (Transparent), 41 (Sticking plaster)
Heterogeneity: not applicable
Test for overall effect: Z = 0.71 (P = 0.48)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours transparent Favours sticking plaster
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Analysis 4.4. Comparison 4 Transparent dressing versus sticking plaster, Outcome 4 Occlusion.
Review: Devices and dressings to secure peripheral venous catheters to prevent complications
Comparison: 4 Transparent dressing versus sticking plaster
Outcome: 4 Occlusion
Study or subgroup Transparent Sticking plaster Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Forni 2012 39/346 36/357 100.0 % 1.12 [ 0.73, 1.72 ]
Total (95% CI) 346 357 100.0 % 1.12 [ 0.73, 1.72 ]
Total events: 39 (Transparent), 36 (Sticking plaster)
Heterogeneity: not applicable
Test for overall effect: Z = 0.51 (P = 0.61)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours transparent Favours sticking plaster
A P P E N D I C E S
Appendix 1. Search strategies
MEDLINE:
1 exp Catheterization, Peripheral/ (8005)
2 (peripheral venous catheter* or PVC).tw. (3869)
3 1 or 2 (11753)
4 exp Occlusive Dressings/ (3380)
5 (securement device* or Statlock or Hubguard).tw. (27)
6 ((occlusive or gauze or tape or polyurethane or permeable or nonpermeable or non-permeable or transparent or antimicrobial) adj3
dressing$).ti,ab. (1506)
7 (opsite or tegaderm or micropore or hypafix).tw. (1015)
8 or/4-7 (5250)
9 3 and 8 (59)
EMBASE:
1 exp Catheterization, Peripheral/ (132218)
2 (peripheral venous catheter* or PVC).tw. (6567)
3 1 or 2 (138442)
4 exp Occlusive Dressings/ (506)
5 (securement device* or Statlock or Hubguard).tw. (54)
6 ((occlusive or gauze or tape or polyurethane or permeable or nonpermeable or non-permeable or transparent or antimicrobial) adj3
dressing$).ti,ab. (2149)
7 (opsite or tegaderm or micropore or hypafix).tw. (1738)
8 or/4-7 (4134)
51Devices and dressings to secure peripheral venous catheters to prevent complications (Review)
Copyright © 2015 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
9 3 and 8 (144)
10 Randomized controlled trials/ (44267)
11 Single-Blind Method/ (18729)
12 Double-Blind Method/ (121977)
13 Crossover Procedure/ (39367)
14 (random$ or factorial$ or crossover$ or cross over$ or cross-over$ or placebo$ or assign$ or allocat$ or volunteer$).ti,ab. (1333989)
15 (doubl$ adj blind$).ti,ab. (149615)
16 (singl$ adj blind$).ti,ab. (14549)
17 or/10-16 (1399725)
18 exp animals/ or exp invertebrate/ or animal experiment/ or animal model/ or animal tissue/ or animal cell/ or nonhuman/ (20843564)
19 human/ or human cell/ (15195392)
20 and/18-19 (15148733)
21 18 not 20 (5694831)
22 17 not 21 (1209068)
23 9 and 22 (50)
CINAHL:
S22S9 AND S21
S21S10 or S11 or S12 or S13 or S14 or S15 or S16 or S17 or S18 or S19 or S20
S20TX allocat* random*
S19(MH “Quantitative Studies”)
S18(MH “Placebos”)
S17TX placebo*
S16TX random* allocat*
S15(MH “Random Assignment”)
S14TX randomi* control* trial*
S13TX ( (singl* n1 blind*) or (singl* n1 mask*) ) or TX ( (doubl* n1 blind*) or (doubl* n1 mask*) ) or TX ( (tripl* n1 blind*) or
(tripl* n1 mask*) ) or TX ( (trebl* n1 blind*) or (trebl* n1 mask*) )
S12TX clinic* n1 trial*
S11PT Clinical trial
S10(MH “Clinical Trials+”)
S9(S4 OR S5 OR S6 OR S7) AND (S3 AND S8)
S8S4 OR S5 OR S6 OR S7
S7TI ( (opsite or tegaderm or micropore or hypafix) ) OR AB ( (opsite or tegaderm or micropore or hypafix) )
S6TI ( ((occlusive or gauze or tape or polyurethane or permeable or non permeable or non-permeable or transparent or antimicrobial)
n3 dressing*) ) OR AB ( ((occlusive or gauze or tape or polyurethane or permeable or non permeable or non-permeable or transparent
or antimicrobial) n3 dressing*) )
S5TI ( (securement device* or Statlock or Hubguard) ) OR AB ( (securement device* or Statlock or Hubguard) )
S4(MH “Occlusive Dressings”)
S3S1 OR S2
S2TI ( (peripheral venous catheter* or PVC) ) OR AB ( (peripheral venous catheter* or PVC) )
S1(MH “Catheterization, Peripheral+”)
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Appendix 2. ’Risk of bias’ table judgement criteria
1. Was the allocation sequence generated adequately?
• Low risk of bias - adequate sequence generation is described in sufficient detail for example, using a computer random number
generator, random number tables, coin tossing or shuffling envelopes
• High risk of bias - non random component in sequence generation is described by the author. This description usually involves
a systematic non-random approach, for example, sequence generated by odd or even date of birth; by a rule based on date of
admission or on hospital or clinic record number.
• Unclear - Insufficient information about the sequence generation provided to make a judgement of risk of bias.
2. Was the allocation sequence adequately concealed?
• Low risk of bias - participants and investigators enrolling participants could not forsee allocation assignment because one of the
following methods was used for allocation concealment: central allocation, for example, via telephone, web-based and pharmacy-
controlled randomisation; sequentially-numbered drug containers of identical appearance; sequentially-numbered opaque, sealed
envelopes.
• High risk of bias - participants or investigators enrolling participants could possibly foresee assignments and thus introduce
selection bias, such as allocation based on: an open random allocation schedule; assignment without appropriate safeguards, for
example non-opaque envelopes or envelopes that were not sequentially-numbered; alternation of rotation; date of birth; case record
number; or any other unconcealed procedure.
• Unclear - Insufficient information about the concealment provided to make a judgement of risk of bias.
3. Blinding of participants and personnel - was knowledge about the allocation of interventions adequately
prevented during the study?
• Low risk of bias - either of the following: no blinding or incomplete blinding, but the review authors judge that the outcome is
not likely to be influenced by the lack of blinding; or blinding of participants and the study personnel ensured, and unlikely that the
blinding could have been broken
• High risk of bias - either of the following: no blinding or incomplete blinding, and the outcome is likely to be influenced by
lack of blinding; or blinding of key study participants and personnel attempted, but likely that the blinding could have been broken
and the outcome is likely to be influenced by lack of blinding.
• Unclear - either of the following: insufficient information provided to permit judgement of risk of bias; or the study did not
address the outcome.
4. Blinding of outcome assessment - was knowledge of the allocated interventions adequately prevented during
the study?
• Low risk of bias - either of the following: no blinding of outcome assessment but the review authors judge that the outcome
measurement is not likely to be influenced by the lack of blinding; or blinding of the outcome assessment ensured, and unlikely that
the blinding could have been broken.
• High risk of bias - either of the following: no blinding of outcome assessment and the outcome measurement is likely to be
influenced by lack of blinding; or blinding of outcome assessment, but likely that the blinding could have been broken, and the
outcome measurement is likely to be influenced by the lack of blinding.
• Unclear - either of the following: insufficient information provided to permit judgement of risk of bias; or the study did not
address this outcome.
5. Were incomplete outcome data adequately addressed?
• Low risk of bias - any one of the following: no missing outcome data; reasons for missing outcome data are unlikely to be related
to true outcome (for survival data, censoring is unlikely to be introducing bias); missing outcome data balanced in numbers across
intervention groups, with similar reasons for missing data across groups; for dichotomous outcome data, the proportion of missing
outcomes compared with observed event risk is not enough to have a clinically relevant impact on the intervention effect estimate; for
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continuous outcome data, plausible effect size (difference in means or standardised difference in means) among missing outcomes is
not enough to have a clinically relevant impact on observed effect size; missing data have been imputed using appropriate methods.
• High risk of bias - any one of the following: reason for missing outcome data is likely to be related to true outcome, with either
imbalance in numbers or reasons for missing data across intervention groups; for dichotomous outcome data, the proportion of
missing outcomes compared with observed event risk is enough to induce clinically relevant bias in intervention effect estimate; for
continuous outcome data, plausible effect size (difference in means or standardised difference in means) among missing outcomes is
enough to induce clinically relevant bias in observed effect size; ‘as-treated’ analysis done with substantial departure of the
intervention received from that assigned at randomisation; potentially inappropriate application of simple imputation.
• Unclear - either of the following: insufficient reporting of attrition/exclusions to permit judgement of low or high risk of bias
(e.g. number randomised not stated, no reasons for missing data provided); the study did not address this outcome.
6. Are reports of the study free of suggestion of selective outcome reporting?
• Low risk of bias - either of the following: the study protocol is available and all of the study’s pre-specified (primary and
secondary) outcomes that are of interest in the review have been reported in the pre-specified way; or the study protocol is not
available but it is clear that the published reports include all expected outcomes, including those that were pre-specified (convincing
text of this nature may be uncommon).
• High risk of bias - any one of the following: not all of the study’s pre-specified primary outcomes have been reported; one or
more primary outcomes is reported using measurements, analysis methods or subsets of the data (e.g. subscales) that were not pre-
specified; one or more reported primary outcomes were not pre-specified (unless clear justification for their reporting is provided,
such as an unexpected adverse effect); one or more outcomes of interest in the review are reported incompletely so that they cannot be
entered in a meta-analysis; the study report fails to include results for a key outcome that would be expected to have been reported for
such a study.
• Unclear - insufficient information provided to permit judgement of risk bias.
7. Other sources of potential bias
• Low risk of bias - the study appears to be free of other sources of bias.
• High risk of bias - there is at least one important risk of bias, for example the study: had a potential source of bias related to the
specific study design used; or had extreme baseline imbalance; or has been claimed to have been fraudulent; or had some other
problem.
• Unclear - there may be a risk of bias, but there is either: insufficient information to assess whether an important risk of bias
exists; or insufficient rationale or evidence that an identified problem will introduce bias.
Appendix 3. Glossary
Colonisation: the presence of bacteria or other micro-organisms in a specific body part or a device in the body
Dwell time: number of hours/days that a device remains in a patient
Erythema: redness or inflammation of the skin
Intravascular device: a catheter or device that is placed within a vessel (vein or artery) and used for intravascular access
Intravascular fluids: liquid that is delivered intravascularly, usually from a fluid bag, via a line or administration set and through an
intravascular device
Peripheral venous catheter (PVC): a flexible, hollow, plastic tube that is inserted into a peripheral vein
Phlebitis: irritation to a vein wall caused by the presence of an intravascular device
Skin integrity: a description of a patient’s skin, whether it is intact or not
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